New Jersey residents could receive quicker access to powerful pain relievers under a bill advancing in the Legislature.
The bill, A-1832 would prevent insurers from requiring people to try more than one pain medication before they would be able to receive the medication that their doctors want to prescribe.
The bill pits advocates for doctors and patients, who say patients shouldn’t be denied powerful drugs like opioids when they need them, against insurers and employers, who emphasize the higher costs and the danger of exposing patients to potentially addictive drugs.
The measure targets a practice known as “fail first protocol” or “step therapy,” in which insurers require that less-expensive medications be tried first. This can lead to a series of less-expensive drugs being tried before the medication preferred by the doctor.
While the state already has rules to prevent step therapy, insurers still delay doctors’ recommended prescriptions by various means, including requiring prior authorizations from the insurer for doctors’ preferred medications.
Under the bill, once one pain medication has been tried and failed, prior authorization for the doctor’s preferred medication wouldn’t be required. In addition, the doctor would determine how long the medication required by the insurer must be tried before moving on to the doctor’s preference.
Timothy J. Martin, a Medical Society of New Jersey lobbyist, said the bill is the right approach for pain medication.
“It is one thing to ask me to fail in my allergy medication for period of time and have the sniffles more than I would normally like to, it’s an entirely different proposition to ask somebody to fail on pain medication before they can move on to the medicine their physician thinks would be more effective,” Martin said. “That provider is in a better position to understand the pain that a patient is going through” than an insurer would be.
The doctor’s preferred prescription would come at a price, both to employers and to the state government, opponents argued.
Sarah McLallen, vice president of the New Jersey Association of Health Plans, noted that prescription costs comprise 15 percent of rising national healthcare costs.
“Fail-first protocols and prior authorization are important tools in helping reduce and prevent the abuse of drugs like pain medications, and they’re also important tools to help reduce and prevent unnecessary costs in the healthcare system,” she said. She noted that the bill would cost the state an additional $5.8 million, because the state would be paying more for pain medication for public employees.
Pfizer’s pain drug Celebrex costs roughly $150 per month, while similar generics cost $10 to $15 per month, McLallen said. In addition, Celebrex’s price increased by 18.7 percent in 2011, while most the prices of most generics decreased.
“When you take away important quality and cost controls such as these, it only adds to the exponentially increasing cost of healthcare,” McLallen said.
Heather Cascone, senior manager of state government affairs for Express Scripts Inc., said allowing prescribers to determine the duration of time for trying medications would undermine an important tool for her company, which processes and pays prescription drug claims.
“Ultimately it’s our goal to keep prescription drugs safe and affordable,” Cascone said. She said pharmacy benefit manager companies like hers can make appropriate decisions based on both clinical safety and cost, without the influence of pharmaceutical manufacturers.
“Turning the authority for step-therapy initiatives over to the prescriber, we believe, would subvert the intent of these programs,” Cascone said.
Continue reading on NJSpotlight.com.
NJ Spotlight is an issue-driven news website that provides critical insight to New Jersey’s communities and businesses. It is non-partisan, independent, policy-centered and community-minded.